ProfileGDS5678 / 1438134_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 35% 36% 36% 35% 35% 37% 37% 35% 38% 36% 36% 36% 36% 36% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8303835
GSM967853U87-EV human glioblastoma xenograft - Control 22.8198836
GSM967854U87-EV human glioblastoma xenograft - Control 32.8155836
GSM967855U87-EV human glioblastoma xenograft - Control 42.7376135
GSM967856U87-EV human glioblastoma xenograft - Control 52.7570735
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9165837
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.890137
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7857635
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8464638
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8119836
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.816936
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7928636
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8149236
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8039336